Ali S M, Harvey H A, Lipton Allan
M S Hershey Medical Center, Hershey, PA, USA.
Clin Orthop Relat Res. 2003 Oct(415 Suppl):S132-7. doi: 10.1097/01.blo.0000092981.12414.7b.
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.
转移性乳腺癌患者的中位生存期为2至3年。仅出现骨转移的患者中,20%在确诊后5年时仍存活。当前的治疗旨在改善生活质量、控制症状以及延长生存期。医学肿瘤学家可使用更新的内分泌和化疗药物来治疗转移性乳腺癌患者。我们将简要回顾转移性乳腺癌治疗方面的新进展。